Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma

Journal of Clinical Oncology

Volumn 36, Issue 1, 2018, Pages 61-67

  Doi, Toshihiko ^a   Piha Paul, Sarina A ^b   Jalal, Shadia I ^c   Saraf, Sanatan ^d   Lunceford, Jared ^d   Koshiji, Minori ^d   Bennouna, Jaafar ^e  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UMR INSERM U892 CNRS 6299   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER PATIENT; COHORT ANALYSIS; CONFERENCE PAPER; CXCL10 GENE; CXCL19 GENE; DECREASED APPETITE; DEHYDRATION; DENTAL CARIES; DISEASE SEVERITY; DRUG SAFETY; ENTEROCOLITIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; FOLLOW UP; GASTROESOPHAGEAL JUNCTION; GENE; GENE EXPRESSION PROFILING; HLA DRA GENE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IDO1 GENE; IFNG GENE; LACRIMATION; LEUKOCYTE COUNT; LIVER DISEASE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; PEMPHIGOID; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIDE EFFECT; STAT1 GENE; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECT; ESOPHAGUS TUMOR; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;

EID: 85039896804     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.74.9846     Document Type: Conference Paper

References (30)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011.
2. Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: Sources, methods andmajor patterns in GLOBOCAN 2012. Int J Cancer 136:E359-E386, 2015.
3. Zhang HZ, Jin GF, Shen HB: Epidemiologic differences in esophageal cancer between Asian and Western populations. Chin J Cancer 31:281-286, 2012.
4. Integrated genomic characterization of oesophageal carcinoma. Nature 541:169-175, 2017.
5. Tew WP, Kelsen DP, Ilson DH: Targeted therapies for esophageal cancer. Oncologist 10:590-601, 2005.
6. D'Journo XB, Thomas PA: Current management of esophageal cancer. J Thorac Dis 6:S253-S264, 2014 (suppl 2).
7. NationalComprehensiveCancerNetwork:NCCN clinical practice guidelines in oncology. Esophageal and esophagogastric junction cancers v.2 2016. https://www.nccn.org/professionals/physician-gls/pdf/esophageal.pdf.
8. Wiedmann MW, Mössner J: New and emerging combination therapies for esophageal cancer. Cancer Manag Res 5:133-146, 2013.
9. Keir ME, Butte MJ, Freeman GJ, et al: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704, 2008.
10. Carter L, Fouser LA, Jussif J, et al: PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 32: 634-643, 2002.
11. Freeman GJ, Long AJ, Iwai Y, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-1034, 2000.
12. Latchman Y, Wood CR, Chernova T, et al: PDL2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261-268, 2001.
13. McDermott DF, Atkins MB: PD-1 as a potential target in cancer therapy. Cancer Med 2:662-673, 2013.
14. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012.
15. He J, Hu Y, Hu M, et al: Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep 5:13110, 2015.
16. Ohigashi Y, Sho M, Yamada Y, et al: Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11:2947-2953, 2005.
17. Derks S, Nason KS, Liao X, et al: Epithelial PDL2 expression marks Barrett's esophagus and esophageal adenocarcinoma. Cancer Immunol Res 3: 1123-1129, 2015.
18. Lu B, Chen L, Liu L, et al: T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. Immunol Res 50:269-275, 2011.
19. Lv L, Pan K, Li XD, et al: The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS One 6:e18219, 2011.
20. Schumacher K, HaenschW, Röefzaad C, et al: Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 61:3932-3936, 2001.
21. Cho Y, Miyamoto M, Kato K, et al: CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 63:1555-1559, 2003.
22. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012.
23. Muro K, Chung HC, Shankaran V, et al: Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, openlabel, phase 1b trial. Lancet Oncol 17:717-726, 2016.
24. Jin Z, Yoon HH: The promise of PD-1 inhibitors in gastro-esophageal cancers: Microsatellite instability vs. PD-L1. J Gastrointest Oncol 7:771-788, 2016.
25. Dolled-Filhart M, Locke D, Murphy T, et al: Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue. Arch Pathol Lab Med 140: 1259-1266, 2016.
26. Ribas A, Robert C, Hodi S, et al: Response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) is associated with an interferon-inflammatory immune gene signature. J Clin Oncol 33, 2015 (suppl; abstr 3001).
27. Seiwert TY, Burtness B, Mehra R, et al: Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol 17:956-965, 2016.
28. Robert C, Schachter J, Long GV, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521-2532, 2015.
29. Garon EB, Rizvi NA, Hui R, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018-2028, 2015.
30. Kudo T, Hamamoto Y, Kato K, et al: Nivolumab treatment for oesophageal squamous-cell carcinoma: An open-label, multicentre, phase 2 trial. Lancet Oncol 18:631-639, 2017.